Latest Conference Articles

July 1st 2017, 8:40pm

ESMO Gastrointestinal Cancers Congress

The novel stemness inhibitor napabucasin in combination with different standard chemotherapy backbones demonstrated promising activity in metastatic pancreatic adenocarcinoma and metastatic colorectal cancer.

July 1st 2017, 8:02pm

ESMO Gastrointestinal Cancers Congress

CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.

July 1st 2017, 3:58am

European Post-Chicago Melanoma / Skin Cancer Meeting

Immune checkpoint inhibitors against PD-1 and PD-L1 are showing promise across clinical trials for patients with Merkel cell carcinoma.

July 1st 2017, 12:39am

ESMO Gastrointestinal Cancers Congress

Aparna Parikh, MD, discusses the potential impact of liquid biopsies in overcoming resistance to targeted therapies in gastrointestinal cancer.

June 30th 2017, 11:29pm

ESMO Gastrointestinal Cancers Congress

Patients with unresectable HCC continue to show statistically significant improvement in overall survival with second-line regorafenib (Stivarga) treatment.

June 30th 2017, 11:23pm

ESMO Gastrointestinal Cancers Congress

Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.

June 30th 2017, 9:39pm

ESMO Gastrointestinal Cancers Congress

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

June 30th 2017, 9:34pm

ESMO Gastrointestinal Cancers Congress

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses liquid biopsies in gastrointestinal cancers.

June 30th 2017, 9:14pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.

June 30th 2017, 8:18pm

State of the Science Summit on Melanoma and Immuno-Oncology

Doug Kondziolka, MD, professor and vice chair of Clinical Research, NYU Langone Medical Center, discusses therapeutic approaches for patients with melanoma who have brain metastases.

June 30th 2017, 8:01pm

State of the Science Summit on Melanoma and Immuno-Oncology

Jeffrey S. Weber, MD, PhD, a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the next steps with the PD-1 inhibitor pembrolizumab (Keytruda) as treatment for patients with melanoma.

June 30th 2017, 6:55pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Monotherapy with potent BRAF inhibitor dabrafenib (Tafinlar) resulted in a disease control rate of 83% in patients with BRAF-mutant melanoma and brain metastases.

June 30th 2017, 5:49pm

State of the Science Summit on Melanoma and Immuno-Oncology

Anna C. Pavlick, DO, discusses adjuvant therapy for patients with high-risk melanoma.

June 30th 2017, 5:29pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.

June 30th 2017, 5:27pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.

June 30th 2017, 3:25am

European Post-Chicago Melanoma / Skin Cancer Meeting

Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.

June 30th 2017, 3:07am

European Post-Chicago Melanoma / Skin Cancer Meeting

Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.

June 30th 2017, 1:36am

ESMO Gastrointestinal Cancers Congress

Julien Taieb, MD, discusses the prognostic value of primary tumor location in colon cancer.

June 30th 2017, 1:02am

State of the Science Summit on Melanoma and Immuno-Oncology

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

June 30th 2017, 12:05am

State of the Science Summit on Melanoma and Immuno-Oncology

Melissa A. Wilson, MD, PhD, discussed the promising results with BRAF/MEK inhibitor combinations in melanoma and what ongoing studies have the potential to alter the landscape again.